A retrospective study analysing safety and efficacy of Tisagenlecleucel in pediatric patients with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia
Latest Information Update: 20 Jan 2023
At a glance
- Drugs Tisagenlecleucel (Primary)
- Indications Precursor B-cell lymphoblastic leukaemia-lymphoma
- Focus Adverse reactions; Therapeutic Use
- 13 Dec 2022 Results describing the landscape of standard cytogenetic risk stratification in patients treated with commercial CD19-CAR T cell therapy (tisagenlecleucel) presented at the 64th American Society of Hematology Annual Meeting and Exposition
- 07 Jun 2022 Results presented at the 58th Annual Meeting of the American Society of Clinical Oncology
- 09 Dec 2021 Results published in the Journal of Clinical Oncology